
    
      This is a multi-centered study conducted in 12-16 collaborative hospitals in Taiwan, using
      tenofovir as antiviral therapy to reduce mother-to-infant transmission. The study group
      recruited pregnant women at 2nd to 3rd trimester receive tenofovir disoproxil fumurate (TDF)
      2011-2018, June, and receive tenofovir alafenamide (TAF) 2018-2021. Control group did not
      receive antiviral treatment. Both group receive mother and infant follow-up up to 12 months
      after delivery.
    
  